Drug intelligence / Profile preview

Ganzhixiao

Development stage: Phase 2
Lead developer: Tongji Hospital
Administration: Oral

Overview

Ganzhixiao is a Traditional Chinese Medicine (TCM) herbal formulation developed for the treatment of metabolic associated fatty liver disease (MAFLD), particularly the damp-heat syndrome type. Typically administered in capsule form, the formula is designed to reduce hepatic steatosis and improve metabolic parameters. Clinical evaluation, including Phase 2 randomized trials, has utilized MRI-proton density fat fraction (MRI-PDFF) as a primary endpoint to measure its efficacy in reducing liver fat content. The development and clinical study of Ganzhixiao are notably associated with researchers such as Dong Hui at Tongji Hospital of Huazhong University of Science and Technology.

Brand names: Ganzhixiao
Other names: Ganzhixiao capsuleGanzhixiao capsules

Beyond the preview

Go deeper on Ganzhixiao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganzhixiao.

Explore the full profile